COVID-19

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous UrticariaCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed…

2 years ago
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic AtrophyAkari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials…

2 years ago
electroCore Provides Select Second Quarter 2023 Financial GuidanceelectroCore Provides Select Second Quarter 2023 Financial Guidance

electroCore Provides Select Second Quarter 2023 Financial Guidance

Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022ROCKAWAY,…

2 years ago
Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in WomenDaré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

Sildenafil Cream Demonstrated Statistically Significant Improvement in Sexual Desire, an Exploratory Endpoint; Improvements in Arousal Lubrication, Orgasm and Sexual Desire…

2 years ago
Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S.Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S.

Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S.

Daxor Adds a Six-Facility Hospital System with ezBVA Lab and Expands Treatment Areas Among Existing Accounts Oak Ridge, TN, July…

2 years ago
National Assessment Highlights Impact of COVID-19 on Pediatric Capabilities of Emergency Departments – With Implications for SurvivalNational Assessment Highlights Impact of COVID-19 on Pediatric Capabilities of Emergency Departments – With Implications for Survival

National Assessment Highlights Impact of COVID-19 on Pediatric Capabilities of Emergency Departments – With Implications for Survival

AUSTIN, TX / ACCESSWIRE / July 10, 2023 / Emergency departments (EDs) have made progress but do not fully meet…

2 years ago
Justera Health Signs LOI to Acquire Juillet Wellness CentreJustera Health Signs LOI to Acquire Juillet Wellness Centre

Justera Health Signs LOI to Acquire Juillet Wellness Centre

Toronto, Ontario--(Newsfile Corp. - July 10, 2023) - Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (formerly ScreenPro Security Inc.) ("Justera" or the…

2 years ago
Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutesOxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes

Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes

Breakthrough in diagnostics testing enables ‘facial recognition for germs’ Collaboration with John Radcliffe Hospital used AI to identify respiratory viruses…

2 years ago
Shineco Subsidiary Receives Marketing Approval from China’s Regulatory Body for its Cardiac 5-Minute TestShineco Subsidiary Receives Marketing Approval from China’s Regulatory Body for its Cardiac 5-Minute Test

Shineco Subsidiary Receives Marketing Approval from China’s Regulatory Body for its Cardiac 5-Minute Test

Registration with the NMPA, China’s Regulatory Equivalent to the FDA, is a Prerequisite to Marketing and Distribution BEIJING, July 10,…

2 years ago